Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293872298> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4293872298 endingPage "69" @default.
- W4293872298 startingPage "67" @default.
- W4293872298 abstract "El síndrome de Guillain-Barré (SGB) es un padecimiento inmunológico poco común que afecta a los nervios periféricos, la causa no es del todo conocida, pero está asociada a infecciones por virus o bacterias. Reportamos el caso de un paciente masculino de 23 años de edad, estudiante del área de la salud, que 24 horas posteriores a recibir la segunda dosis de la vacuna COVID BNT162b2 mRNA (Pfizer-Biontech) presentó debilidad proximal de extremidad superior derecha, posteriormente en la izquierda con progresión descendente y distal. En general se han publicado casos de SGB relacionados a las vacunas contra COVID-19 siendo la más común la BNT162b2 que es de mRNA, también hay casos publicados posteriores a la vacuna AZD1222 (ChAdOx1) que es de vector viral no replicante. Se calcula que la incidencia de SGB en 0.43 por cada 100,00 dosis aplicadas, por debajo de la incidencia nacional registrada de 1.1-1.8 por cada 100,000 habitantes al año. Es importante mencionar que si bien se puede presentar SGB posterior a la vacunación contra COVID-19, esta incidencia es mucho menor a lo presentado en la comunidad en México asociado a otros padecimientos, considerándose más común la presencia de casos relacionados a padecimientos infecciosos gastrointestinales. Guillain-Barré syndrome (GBS) is a rare immune disorder that affects peripheral nerves and the cause is not known completely, but it is associated with infections by viruses or bacteria. We report the case of a 23-year-old male patient, a health student, who start 24 hours after received the second dose of COVID-19 vaccine, with proximal weakness of the right upper limb, later in the left side with descending and distal progression. GBS cases related to COVID-19 vaccines have been published, the most common being BNT162b2, which is mRNA, there are also cases published after the AZD1222 (ChAdOx1) vaccine, which is a non-replicating viral vector. The incidence of GBS is estimated at 0.43 per 100.00 doses applied, under registered national incidence of 1.1-1.8 per 100,000 persons per year. It is important to mention that although GBS can occur after vaccination against COVID-19, this incidence is much lower than which occurs in the community in Mexico associated with other diseases, considering more common the presence of cases related to infectious gastrointestinal diseases." @default.
- W4293872298 created "2022-09-01" @default.
- W4293872298 creator A5045984364 @default.
- W4293872298 creator A5060152132 @default.
- W4293872298 date "2022-08-01" @default.
- W4293872298 modified "2023-10-02" @default.
- W4293872298 title "Case report of Guillain-Barré Syndrome after COVID BNT162b2 mRNA vaccine" @default.
- W4293872298 cites W3017018770 @default.
- W4293872298 cites W3170053887 @default.
- W4293872298 cites W3175218588 @default.
- W4293872298 cites W3177233384 @default.
- W4293872298 cites W3191936386 @default.
- W4293872298 cites W3201388154 @default.
- W4293872298 cites W3205396847 @default.
- W4293872298 doi "https://doi.org/10.1016/j.vacune.2022.05.004" @default.
- W4293872298 hasPublicationYear "2022" @default.
- W4293872298 type Work @default.
- W4293872298 citedByCount "0" @default.
- W4293872298 crossrefType "journal-article" @default.
- W4293872298 hasAuthorship W4293872298A5045984364 @default.
- W4293872298 hasAuthorship W4293872298A5060152132 @default.
- W4293872298 hasConcept C116675565 @default.
- W4293872298 hasConcept C126322002 @default.
- W4293872298 hasConcept C159047783 @default.
- W4293872298 hasConcept C203014093 @default.
- W4293872298 hasConcept C2778691916 @default.
- W4293872298 hasConcept C2779134260 @default.
- W4293872298 hasConcept C3006700255 @default.
- W4293872298 hasConcept C3007834351 @default.
- W4293872298 hasConcept C3008058167 @default.
- W4293872298 hasConcept C524204448 @default.
- W4293872298 hasConcept C71924100 @default.
- W4293872298 hasConceptScore W4293872298C116675565 @default.
- W4293872298 hasConceptScore W4293872298C126322002 @default.
- W4293872298 hasConceptScore W4293872298C159047783 @default.
- W4293872298 hasConceptScore W4293872298C203014093 @default.
- W4293872298 hasConceptScore W4293872298C2778691916 @default.
- W4293872298 hasConceptScore W4293872298C2779134260 @default.
- W4293872298 hasConceptScore W4293872298C3006700255 @default.
- W4293872298 hasConceptScore W4293872298C3007834351 @default.
- W4293872298 hasConceptScore W4293872298C3008058167 @default.
- W4293872298 hasConceptScore W4293872298C524204448 @default.
- W4293872298 hasConceptScore W4293872298C71924100 @default.
- W4293872298 hasLocation W42938722981 @default.
- W4293872298 hasOpenAccess W4293872298 @default.
- W4293872298 hasPrimaryLocation W42938722981 @default.
- W4293872298 hasRelatedWork W3015357115 @default.
- W4293872298 hasRelatedWork W3028940391 @default.
- W4293872298 hasRelatedWork W3032377983 @default.
- W4293872298 hasRelatedWork W3178186717 @default.
- W4293872298 hasRelatedWork W3184386184 @default.
- W4293872298 hasRelatedWork W3189363561 @default.
- W4293872298 hasRelatedWork W3210429291 @default.
- W4293872298 hasRelatedWork W4210401150 @default.
- W4293872298 hasRelatedWork W4283688183 @default.
- W4293872298 hasRelatedWork W4287374796 @default.
- W4293872298 hasVolume "23" @default.
- W4293872298 isParatext "false" @default.
- W4293872298 isRetracted "false" @default.
- W4293872298 workType "article" @default.